keyword
MENU ▼
Read by QxMD icon Read
search

Tofacitinib

keyword
https://www.readbyqxmd.com/read/28213386/erratum-efficacy-and-safety-of-tofacitinib-following-inadequate-response-to-conventional-synthetic-or-biologic-diseasemodifying-antirheumatic-drugs
#1
(no author information available yet)
No abstract text is available yet for this article.
March 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28210825/recovery-of-nail-dystrophy-potential-new-therapeutic-indication-of-tofacitinib
#2
REVIEW
Jose A Jaller, Juan J Jaller, Antonio M Jaller, Juan J Jaller-Char, Sineida Berbert Ferreira, Rachel Ferreira, Morton Scheinberg
Nail dystrophy is a heterogeneous skin condition and in some subtypes, is associated with autoimmune diseases in particular psoriasis and psoriatic arthritis. In this report, we show that tofacitinib, a novel therapy for rheumatoid arthritis, appears to be beneficial in patients with nail disease refractory to other conventional modes of therapy.
February 16, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28209624/tofacitinib-for-induction-and-maintenance-therapy-of-crohn-s-disease-results-of-two-phase-iib-randomised-placebo-controlled-trials
#3
Julian Panés, William J Sandborn, Stefan Schreiber, Bruce E Sands, Séverine Vermeire, Geert D'Haens, Remo Panaccione, Peter D R Higgins, Jean-Frederic Colombel, Brian G Feagan, Gary Chan, Michele Moscariello, Wenjin Wang, Wojciech Niezychowski, Amy Marren, Paul Healey, Eric Maller
OBJECTIVE: Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and maintenance treatment in patients with moderate-to-severe Crohn's disease (CD). DESIGN: We conducted two randomised, double-blind, placebo-controlled, multicentre phase IIb studies. Adult patients with moderate-to-severe CD were randomised to receive induction treatment with placebo, tofacitinib 5 or 10 mg twice daily for 8 weeks...
February 16, 2017: Gut
https://www.readbyqxmd.com/read/28201942/correction-to-early-clinical-response-to-tofacitinib-treatment-as-a-predictor-of-subsequent-efficacy-results-from-two-phase-3-studies-of-patients-with-moderate-to-severe-plaque-psoriasis
#4
(no author information available yet)
No abstract text is available yet for this article.
February 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28197884/therapies-of-early-advanced-and-late-onset-forms-of-axial-spondyloarthritis-and-the-need-for-treat-to-target-strategies
#5
REVIEW
Nurullah Akkoc, Gercek Can, Salvatore D'Angelo, Angela Padula, Ignazio Olivieri
PURPOSE OF REVIEW: This study aims to provide an update on current status of pharmacological therapies in early and advanced stages of axial spondyloarthritis (axSpA), as well as its late onset forms, and to discuss the need for treat to target strategies in this entity. RECENT FINDINGS: Efficacy of TNF inhibitors has been assessed in randomized controlled trials in axSpA, which included patients who had non-radiographic axSpA according to the ASAS classification criteria...
February 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28193636/evaluation-of-jak3-biology-in-autoimmune-disease-using-a-highly-selective-irreversible-jak3-inhibitor
#6
Fiona Elwood, David Witter, Jennifer Piesvaux, Brian Kraybill, Nathan Bays, Carla Alpert, Peter Goldenblatt, Yujie Qu, Irena Ivanovska, Hyun-Hee Lee, Chi-Sung Chiu, Hao Tang, Mark E Scott, Sujal Deshmukh, Mark Zielstorff, Alan Byford, Kalyan Chakravarty, Lauren Dorosh, Alexy Rivkin, Joel Klappenbach, Bo-Sheng Pan, Ilona Kariv, Christopher Dinsmore, Deborah Slipetz, Peter Dandliker
Reversible Janus kinase (JAK) inhibitors such as Tofacitinib(Changelian, et al., 2003;Flanagan, et al., 2010) and Decernotinib(Farmer, et al., 2015;Mahajan, et al., 2015) block cytokine signaling and are efficacious in treating autoimmune diseases (Kremer, et al., 2009;Fleischmann, et al., 2015;Fleischmann, et al., 2015;Krueger, et al., 2016;Sandborn, et al., 2012). However therapeutic doses are limited due to inhibition of other JAK/STAT pathways associated with hematopoiesis, lipid biogenesis, infection and immune responses(Kahn C, 2012)...
February 13, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28176964/efficacy-and-safety-of-biological-and-targeted-synthetic-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#7
Alexandre Sepriano, Andrea Regel, Désirée van der Heijde, Jürgen Braun, Xenofon Baraliakos, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
OBJECTIVES: To update the evidence for the efficacy and safety of (b)biological and (ts)targeted-synthetic disease-modifying anti-rheumatic drugs (DMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2016 update of the Assessment of SpondyloArthritis international Society/European League Against Rheumatism (ASAS/EULAR) recommendations for the management of axSpA. METHODS: Systematic literature review (2009-2016) for randomised controlled trials (RCT), including long-term extensions, strategy trials and observational studies (the latter was only for safety assessment and a comparator was required)...
2017: RMD Open
https://www.readbyqxmd.com/read/28174992/p118-balancing-jak-stat-signaling-with-tofacitinib-in-monocytes-of-healthy-controls-and-ibd-patients
#8
A F Cordes, E Lenker, T Weinhage, G Varga, D Foell
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28173034/p619-tofacitinib-for-the-treatment-of-resistant-ulcerative-colitis-the-university-of-chicago-experience
#9
R Weisshof, M Aharoni Golan, A Masching, D T Rubin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28173029/p662-tofacitinib-for-induction-of-remission-in-ulcerative-colitis-systematic-review-and-meta-analysis
#10
P Paschos, A Katsoula, O Giouleme, A Tsapas
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172962/p467-maintenance-of-quality-of-life-improvement-in-a-phase-3-study-of-tofacitinib-for-patients-with-moderately-to-severely-active-ulcerative-colitis
#11
J Panés, D T Rubin, S Vermeire, J O Lindsay, B E Sands, C Su, G Friedman, H Zhang, C Kayhan, A Manuchehri, P Healey
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172713/op032-efficacy-and-safety-of-oral-tofacitinib-as-maintenance-therapy-in-patients-with-moderate-to-severe-ulcerative-colitis-results-from-a-phase-3-randomised-controlled-trial
#12
W J Sandborn, B E Sands, S Danese, G R D'Haens, S Vermeire, S Schreiber, B Feagan, W Reinisch, G Friedman, D Woodworth, H Zhang, N Lawendy, W Niezychowski, C Su, J Panés
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172635/op031-long-term-safety-and-tolerability-of-oral-tofacitinib-in-patients-with-crohn-s-disease-results-from-a-phase-2-open-label-48-week-extension-study
#13
J Panés, G R D'Haens, P D R Higgins, L Mele, M Moscariello, G Chan, W Wang, W Niezychowski, C Su, E Maller
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172575/dop074-pharmacokinetics-and-exposure-response-of-tofacitinib-in-a-phase-3-maintenance-study-in-ulcerative-colitis-patients
#14
A Mukherjee, G R D'Haens, W J Sandborn, S Tsuchiwata, C Vong, C Deng, R Xie, A Hazra, S W Martin, G Friedman, W Niezychowski, C Su
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28164724/jak-inhibition-in-inflammatory-bowel-disease
#15
Pablo Olivera, Silvio Danese, Laurent Peyrin-Biroulet
Current available treatments for inflammatory bowel disease (IBD) have some limitations and new options are needed. Several new molecules are being tested for the treatment of IBD and other immune-mediated inflammatory diseases. Among them, Janus kinase (JAK) inhibitors seem to have the lead, since tofacitinib has received regulatory approval in 2012 for the treatment of rheumatoid arthritis, and also it has shown a favorable risk-benefit ratio in phase 3 studies for ulcerative colitis, both in anti-TNF naïve and anti-TNF experienced patients...
February 4, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28148840/therapy-with-ctla4-ig-and-an-antiviral-monoclonal-antibody-controls-chikungunya-virus-arthritis
#16
Jonathan J Miner, Lindsey E Cook, Jun P Hong, Amber M Smith, Justin M Richner, Raeann M Shimak, Alissa R Young, Kristen Monte, Subhajit Poddar, James E Crowe, Deborah J Lenschow, Michael S Diamond
In 2013, chikungunya virus (CHIKV) transmission was documented in the Western Hemisphere, and the virus has since spread throughout the Americas with more than 1.8 million people infected in more than 40 countries. CHIKV targets the joints, resulting in symmetric polyarthritis that clinically mimics rheumatoid arthritis and can endure for months to years. At present, no approved treatment is effective in preventing or controlling CHIKV infection or disease. We treated mice with eight different disease-modifying antirheumatic drugs and identified CLTA4-Ig (abatacept) and tofacitinib as candidate therapies based on their ability to decrease acute joint swelling...
February 1, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28145906/safety-of-tofacitinib-in-the-treatment-of-rheumatoid-arthritis-in-latin-america-compared-with-the-rest-of-the-world-population
#17
Oswaldo M Castañeda, Felix J Romero, Ariel Salinas, Gustavo Citera, Eduardo Mysler, Oscar Rillo, Sebastiao C Radominski, Mario H Cardiel, Juan J Jaller, Carlos Alvarez-Moreno, Dario Ponce de Leon, Graciela Castelli, Erika G García, Kenneth Kwok, Ricardo Rojo
OBJECTIVE: Rheumatoid arthritis (RA) is a chronic, autoimmune disease characterized by joint destruction. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post hoc analysis assessed the safety of tofacitinib in Latin American (LA) patients with RA versus the Rest of World (RoW) population. METHODS: Data were pooled from 14 clinical studies of tofacitinib: six Phase 2, six Phase 3 and two long-term extension studies. Incidence rates (IRs; patients with events/100 patient-years of treatment exposure) were calculated for safety events of special interest combined across tofacitinib doses...
February 1, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28143815/long-term-safety-of-tofacitinib-for-the-treatment-of-rheumatoid-arthritis-up-to-8-5%C3%A2-years-integrated-analysis-of-data-from-the-global-clinical-trials
#18
Stanley B Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R Curtis, Eun Bong Lee, Peter Nash, Kevin L Winthrop, Christina Charles-Schoeman, Krishan Thirunavukkarasu, Ryan DeMasi, Jamie Geier, Kenneth Kwok, Lisy Wang, Richard Riese, Jürgen Wollenhaupt
OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. METHODS: Data were pooled for all tofacitinib-treated patients (data cut-off: 31 March 2015). Incidence rates (IRs; patients with event/100 patient-years) and 95% CIs are reported for adverse events (AEs) of interest...
January 31, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28133877/efficacy-of-topical-tofacitinib-a-janus-kinase-inhibitor-in-the-treatment-of-plaque-psoriasis
#19
Nooshin Bagherani, Bruce R Smoller
No abstract text is available yet for this article.
January 30, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28130206/tofacitinib-in-patients-with-ankylosing-spondylitis-a-phase-ii-16-week-randomised-placebo-controlled-dose-ranging-study
#20
Désirée van der Heijde, Atul Deodhar, James C Wei, Edit Drescher, Dona Fleishaker, Thijs Hendrikx, David Li, Sujatha Menon, Keith S Kanik
OBJECTIVES: To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). METHODS: In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dose-ranging trial, adult patients with active AS were randomised (N=51, 52, 52, 52, respectively) to placebo or tofacitinib 2, 5 or 10 mg twice daily. The primary efficacy endpoint was Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response rate at week 12...
January 27, 2017: Annals of the Rheumatic Diseases
keyword
keyword
9254
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"